New STAMPEDE data support earlier CHAARTED trial results

So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …

This year’s crop of ASCO abstracts now available on line

Before we have even made it to the annual meeting of the American Urological Association (AUA, starting in New Orleans tomorrow), the abstracts for the annual meeting of the American Society for Clinical Oncology (ASCO, starting in Chicago in another couple of weeks) have now been made available. … READ MORE …

Re-classification rates on repeat biopsy for men on active surveillance in the Hopkins cohort

So there is an interesting new paper on the ramifications of active surveillance in the forthcoming June issue of the Journal of Urology — based on the extensive data now collected by the Johns Hopkins group through their very conservative active surveillance cohort of > 1,200 men accumulated since 1995. … READ MORE …

A genetic reason for cognitive impairment among men on ADT?

In a paper just published on line, we finally have some sound, prospective, comparative data confirming that androgen deprivation therapy (ADT) is associated with significant risk for effects on mental cognition among men with prostate cancer when used for 6 months or longer. … READ MORE …

Abiraterone acetate and the “food effect”

For a while now there have been questions about whether taking abiraterone acetate with food as opposed to without food could be clinically beneficial for patients.

A new paper by Stover et al. has provided us with a little more information on this topic (but not a lot!).

Here in the USA, the manufacturer clearly states that

  • “No food should be eaten 2 hours before and 1 hour after taking [abiraterone];”
  • Abiraterone should be taken on an empty stomach; and
  • “Taking [abiraterone] with food may cause more of the medicine to be absorbed by the body than is needed and this may cause side effects.”

(We have added emphasis to the word “may” in this last sentence.)

In fact, what is known is that combining abiraterone acetate with food may (that word again) result in additional inhibition of enzymes involved in the androgen synthesis process association with progressive, castration-resistant prostate cancer (CRPC). This has two possible implications:

  • Some men may be able to use abiraterone acetate initially at lower doses if it is combined with food.
  • Some men who start to progress on a standard dose of abiraterone acetate may be able to take that standard dose with food and gain a clinical benefit (but at potential risk of an increase in side effects).

So let’s be very clear:

  • Neither of these things should be done by any patient without an initial discussion with his doctor.
  • Starting on the standard dose of abiraterone acetate and taking it with food is probably not a very good idea, because if you are one of those patients at significant risk for side effects to this drug, you are going to make that risk significantly worse!

Having said that, let’s look at what Stover et al. did and learned.

They carried out chart reviews on a total of 60 men with metastatic CRPC who were treated with abiraterone between April 1, 2011 and December 31. Of these 60 men, 19 switched from taking abiraterone without food to taking it with food at the time of their initial PSA progression on abiraterone during the study period.

Here is what the authors found:

  • Among the 19 men who switched administration from without food to with food,
    • 14/19 patients (74 percent) had previously had an initial response to abiraterone when taking it without food.
    • 3/19 patients (16 percent) had a PSA decrease within 3 months when taking abiraterone with food.
    • All three responders to the switch had been initial responders to abiraterone when taking it without food
    • Testosterone levels declined in 5/7 patients (71 percent) who switched to taking abiraterone with food.
  • Median time on abiraterone therapy for the 19 men who switched to taking abiraterone with food on initial progression was 100 days longer than among the 41 men who continued taking abiraterone without food.
  • There were no observable increases in toxicity of  abiraterone among the men taking with with food as compared to those taking it without.

Stover et al. reach a very basic conclusion:

Some men with mCRPC may benefit from taking AA with food.

And at the moment that may be the best that we can say.

Prospective trials are being conducted to investigate the food effects of abiraterone. One small trial with 25 patients has been completed (but not yet reported); another trial — with 72 patients — is ongoing. But what is certainly worth knowing is that if you are receiving treatment with abiraterone acetate for CRPC (without food at time of drug administration), and you have an in initial, meaningful PSA response to treatment, then when you show initial signs of PSA progression you may want to talk to your doctors about switching to taking the drug with food … but do talk to your doctor about this; don’t just do it on your own.

Check what you know about diagnosis of prostate cancer

There’s a new slide presentation on the Medscape web site that is designed to help primary care physicians keep up to date on the initial diagnosis of prostate cancer and its implications. … READ MORE …

Statin therapy appears to extend progression-free survival for men on ADT

A combination of two studies by a group of researchers at the Dana-Farber Cancer Institute in Boston has provided some further evidence of the potential benefits of statin therapy for men being treated with androgen deprivation therapy (ADT) … but the evidence is preliminary and needs validation. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,283 other followers